Bond.az White LogoBond.az Black Logo

Paramount Gets Consents for WBD Debt Amendments

Paramount gets consents for WBD debt amendments involving $17.2 billion notes. Details on exchange offers and tender offers.

Michael Brown
ByMichael Brown- Senior Editor
|
0

Paramount Skydance Corporation (NASDAQ:PSKY) announced that Warner Bros. Discovery has received the required consents for proposed amendments to indentures governing approximately $17.2 billion in senior unsecured notes.

With a market cap of $11.6 billion, Paramount carries total debt of $16.6 billion. Its stock trades at $10.37, down 34% over the past six months.

Supplemental indentures effectuating the amendments were executed on Monday and became effective immediately, but will only become operative upon the payment date of the consent solicitations, expected around Thursday.

The consent solicitations were made in connection with Paramount's proposed acquisition of Warner Bros. Discovery. Approximately $12.1 billion and €0.6 billion of WBD notes will be eligible to participate in exchange offers, while approximately $2.4 billion will be eligible for tender offers.

The series of notes receiving consents include various maturities from 2027 to 2052, with interest rates between 3.625% and 6.350%. An additional $2.5 billion of WBD's unsecured notes are not subject to the offers, and approximately $0.1 billion of eligible notes did not receive valid consents.

Holders of WBD notes were required to deliver consents in the consent solicitations to participate in the exchange and tender offers. The offers are being made solely by Paramount and not by Warner Bros. Discovery or its issuers.

The exchange offers and tender offers will expire at 5:00 p.m. New York time on June 17, 2026, subject to extension. Settlement is conditioned on the closing of the acquisition. Paramount stated it anticipates extending the expiration date until the consummation of the acquisition.

BofA Securities and Citigroup are serving as dealer managers. Global Bondholder Services Corporation is acting as exchange agent and information agent.

More News
Today / 13:34
|
406

FuriosaAI Partners with Broadcom on 3rd Gen AI Chip

FuriosaAI partners with Broadcom to develop 3rd gen AI chip with 2nm process and HBM4 memory. Sampling starts H1 2028.

0
Today / 13:33
|
686

Hippocratic AI hits 10 million patient calls

Hippocratic AI's Polaris system hits 10 million patient calls on DigitalOcean with 99.9% safety score. Over 180 million interactions handled.

0
Today / 13:31
|
400

Mastercard Gets NY BitLicense

Mastercard subsidiary receives New York BitLicense for digital asset activities. Regulatory approval for crypto operations.

0
Today / 12:34
|
406

Ernexa Advances ERNA-101 Toward Q3 IND Filing

Ernexa Therapeutics advances ERNA-101 toward Q3 IND filing. The company has completed process development and moved to GMP manufacturing for clinical trials.

0
Today / 12:33
|
604

Alpha Modus Launches AI Platform for Physical Retail Stores

Alpha Modus launches ARIA, an AI platform for physical retail stores. It uses existing infrastructure and delivers real-time decisions.

0
Today / 12:32
|
478

VolitionRx Q1 Revenue Surges 300%, Nears Vet Milestone

VolitionRx Q1 revenue jumps 300% to $1M. Company nears vet milestone with Nu.Q test. Stock up 18%. Analyst targets $16-$24.

0
Today / 11:36
|
615

ProLogium SPAC Merger Valued at $3.8B

ProLogium, a solid-state battery manufacturer, goes public via SPAC merger at $3.8 billion valuation on Nasdaq.

0
Today / 11:34
|
415

Newcleo to Go Public via SPAC Merger at $2.4B Valuation

Newcleo merges with SPAC NewHold at $2.4B valuation, lists on Nasdaq as NWCL. PIPE of $220M included. Transaction expected to close in 2026.

0
Today / 11:33
|
285

Erdene publishes 2026 shareholder letter, schedules meeting

Erdene Resource Development Corp. published its 2026 shareholder letter and scheduled its annual meeting. Details on the Bayan Khundii gold mine operations.

0
Today / 09:02
|
855

FP-001 42 mg Clinical Trial Completed

Foresee Pharmaceuticals completes Phase 3 trial for FP-001 42 mg for precocious puberty. FDA submission planned for 2026. CAMCEVI 21mg approved in Europe.

0
Today / 07:05
|
446

Eden Research director resigns

Eden Research non-executive director Derek McAllan resigns due to ill health. Rob Cridland appointed interim Audit Committee chair.

0
Today / 06:31
|
362

HgCapital Trust invests £11m in Rightsline software

HgCapital Trust invests £11 million in Rightsline, a rights and royalties management software provider, as part of a $500M growth round.

0
...